ClinicalTrials.Veeva

Menu

Effects of Botox in Obstructed Defecation Syndrome

Mass General Brigham logo

Mass General Brigham

Status and phase

Terminated
Phase 2

Conditions

Obstructed Defecation Syndrome (ODS)

Treatments

Drug: Normal Saline
Drug: Botulinum Toxin-A

Study type

Interventional

Funder types

Other

Identifiers

NCT02160288
MGH2014-P-000406

Details and patient eligibility

About

The purpose of this study is to determine if Botulinum Toxin-A (Botox) injection will improve symptoms of constipation in obstructed defecation syndrome (ODS).

Full description

Constipation represents one of the five most common physician diagnoses for gut disorders. Obstructed defecation syndrome (ODS) is an under-treated condition which accounts for 30%- 50% of all patients with constipation and it is more common as people age. ODS is due to the abnormal contraction of the puborectalis muscle (a muscle around the anus that should relax during defecation).

Biofeedback therapy and medical management are the standards of care for ODS. Typically patients are first managed with dietary modifications (fiber supplementation, increased fluids) and medication (laxatives, enemas). If constipation is not improved, they will undergo biofeedback, which lasts from 3-8 sessions on average. Biofeedback acts on the cause of ODS and it has good short-term success, but around 50%-70% of treated patients re-experience constipation after one year. The main drawbacks of biofeedback for ODS are the facts that it is expensive, time-consuming, available in few select-centers and its success depends very much on the provider. Biofeedback is delivered in multiple 1-hour clinic sessions, so many patients don't finish all recommended sessions and their constipation may recur faster.

Botox also acts on the cause of ODS and was shown to improve constipation within 1-3 weeks after the injection. Botox is delivered as a one-time injection in the puborectalis muscle and external anal sphincter (the muscle right around the anus). The injection can be performed in the clinic under local anesthesia, and the patient goes home afterwards. Currently, Botox is used for treatment of patients who fail biofeedback and medical management, to avoid the options of last resort (resection of the colon with stoma). To this day, no adequately designed study has confirmed that Botox is indeed superior to placebo (normal saline) for the treatment of ODS. The results from this study will provide valuable data on the ability of Botox to improve symptoms of constipation and the duration of its effect. This project has the potential to increase the availability of effective treatments for ODS.

Enrollment

1 patient

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Males and females 18 years or older of all races and backgrounds

  • Competent to give informed consent

  • Meet the Rome III diagnostic criteria for functional constipation

  • Inability to relax the puborectalis muscle at electromyography

  • Altomare Obstructed Defecation Syndrome score of 15 points or above

  • Failure of treatment with 2 conservative measures which may be as follows:

    • 1 laxative (osmotic or stimulant) for 2 weeks
    • 1 fiber supplement for one month
    • And/or trial of biofeedback for at least 4 sessions

Exclusion criteria

  • Previous treatment with Botox (possible antibodies)
  • Known hypersensitivity to any of the components of the toxin
  • Medication regimen includes narcotics
  • Previous radiation therapy to the anal canal and rectum
  • Prior proctectomy
  • Presence of unhealed and symptomatic anal fissure
  • Presence of anal pain
  • Presence of fecal incontinence
  • Presence of full thickness rectal prolapse
  • Presence of internal sphincter myopathy
  • Inflammatory bowel disease or proctitis
  • Pregnancy or breast-feeding
  • Subject is currently enrolled/ just finished participating in a clinical trial in which the intervention/ its carry-over effect may interact with the intervention in this trial

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

1 participants in 2 patient groups, including a placebo group

Botulinum Toxin-A
Active Comparator group
Description:
Patients will receive Botulinum Toxin-A (Botox) injected in the puborectalis muscle and external anal sphincter. We will use 100 units of Botox, a dose with a good safety profile that has been proven to work in previous studies performed in adults.
Treatment:
Drug: Botulinum Toxin-A
Normal saline
Placebo Comparator group
Description:
Patients will receive normal saline (placebo) injected in the puborectalis muscle and external anal sphincter.
Treatment:
Drug: Normal Saline

Trial documents
2

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems